Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients. 2016

Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
Department of Medicine, Léon Bérard Center, University of Lyon, Lyon, France.

TPF (docetaxel, cisplatin, fluorouracil) is the standard chemotherapy used for induction in locally advanced head and neck squamous cell carcinoma (LAHNSCC). Its toxicity limits it to younger patients with good functional status and without significant comorbidity. Since modified TPF (mTPF) demonstrated higher tolerability with similar efficacy in gastric cancer, we tested this scheme on frail patients.From July 2010 to July 2014, the files of the 48 patients treated for LAHNSCC with mTPF in three French institutions were retrospectively collected.mTPF was chosen because of age>70 years, or severe denutrition, or PS>1, or severe comorbidities or after severe toxicity of standard TPF. During the first 4 cycles, 2 patients died, 14 secondary hospitalizations were required and 10 patients stopped treatment due to no lethal toxicity. Two patients died during radiotherapy.The response rate was 83% (19% complete response). With a median follow-up of 15.2 months, 4 patients died during treatment, 8 died of non-head and neck cancer related disorders, 18 progressed (17 deaths) and 18 were free of disease. The median overall survival was 18.5 months (95% IC: 16.9-30.0).mTPF is effective in terms of response rate compared with the standard TPF and could become a new option in induction for frail patients with LAHNSCC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
January 2006, Anticancer research,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
May 2014, Japanese journal of clinical oncology,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
February 2005, Nihon Jibiinkoka Gakkai kaiho,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
January 2013, Frontiers in oncology,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
March 2011, Iranian Red Crescent medical journal,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
January 2019, Journal of cancer research and therapeutics,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
January 2004, British journal of cancer,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
November 2010, Oncology reports,
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
May 2005, Clinical oncology (Royal College of Radiologists (Great Britain)),
Jérôme Fayette, and Clara Fontaine-Delaruelle, and Alexis Ambrun, and Clémentine Daveau, and Marc Poupart, and Antoine Ramade, and Philippe Zrounba, and Eve-Marie Neidhardt, and Julien Péron, and Alpha Diallo, and Philippe Céruse
September 1997, Oncology (Williston Park, N.Y.),
Copied contents to your clipboard!